What do retatrutide users report, and does it match the trials?

The short answer

Evidence tier: 4 — the user themes are self-reported and unverified; the trial figures they are checked against are Tier 1 Phase 3 results from TRIUMPH-1.

Retatrutide reviews online are mostly positive about weight loss and appetite control. The most common complaints are skin sensitivity, a higher resting heart rate, and appetite that comes back between doses. Those complaints match the Phase 3 data: in TRIUMPH-1, dysesthesia (abnormal skin sensation) affected about 12% of people on the two higher doses. Every user report comes from unapproved, research-grade product, because retatrutide is not approved anywhere as of November 2026.

For background on the molecule itself, see the retatrutide profile; for the drug most users compare it with, see the tirzepatide profile.

Where do these reviews come from?

Evidence tier: 4 — our own anonymised Reddit dataset, classified by keyword and model; the method is published but not independently audited.

We analysed 301 retatrutide posts collected by our Reddit signal pipeline between 8 June and 3 November 2026. About 69% came from r/Retatrutide; the rest came from r/Peptides, r/Biohacking and GLP-1 communities. Our classifier sorted them into dosing questions (160), experience reports (123) and side-effect reports (18).

The data is anonymised: we store no usernames and quote no one directly. It also carries heavy bias. People post when something is going very well or very badly, nobody verifies doses or product identity, and many posters use several compounds at once. Read the patterns below as "what people are talking about", not as response rates.

What do users say about weight loss on retatrutide?

Evidence tier: 4 — reported losses are unverified self-reports; the trial table below is Tier 1 data from Lilly's Phase 3 programme (NCT05929066).

Experience reports skew positive. The tone was positive in 146 posts and negative in 31. The posts that gave numbers reported losses between roughly 10 and 140 lb, and the larger figures came from people reporting six months or more of use. Many described "food noise" disappearing, which was the single most common theme in experience posts.

The trial results are the more reliable benchmark:

TRIUMPH-1 percentages are the efficacy estimand reported by Lilly; the treatment-regimen figures were slightly lower (−25.0% at 12 mg). At the lower doses, the efficacy estimand was −19.0% at 4 mg and −25.9% at 9 mg.

Trial results are given as percentages, while users post pounds, so it helps to translate. For someone starting at 250 lb, a 28.3% average loss would be about 71 lb; for someone starting at 200 lb, about 57 lb. A 140 lb loss would need a starting weight near 500 lb to match the trial average, so the top of the community range most likely reflects very high starting weights, long use, or both.

Two further caveats apply. Users rarely report how long they have been on a stable dose, and research-grade vials have no verified concentration, so "4 mg" in a post may not be 4 mg.

How do retatrutide's trial results compare with tirzepatide's?

Evidence tier: 2 — cross-trial comparison of separate randomised trials; no head-to-head result has been published.

Many posters switch from tirzepatide, so its trials are the natural benchmark. These figures come from separate trials with different populations and lengths, so they are not a direct contest:

The Phase 2 trial, in 338 adults with obesity, showed weight still falling at 48 weeks, which TRIUMPH-1 later confirmed over a longer period. SURMOUNT-1 enrolled 2,539 adults without diabetes, a population similar to TRIUMPH-1's.

A direct answer is on the way. TRIUMPH-5 (NCT06662383) compares retatrutide with tirzepatide in about 800 adults with obesity and was listed as active but no longer recruiting in November 2026.

What side effects do users report?

Evidence tier: 4 — the themes are self-reported; the rates quoted beside them are Tier 1 TRIUMPH-1 and Phase 2 trial data.

These are the recurring themes, roughly in order of how often they came up:

• Skin sensitivity or "sunburn" feeling. Posters describe burning, tingling or painful skin, often in the legs, sometimes building for weeks and then fading. In TRIUMPH-1, dysesthesia hit 5.1% at 4 mg, 12.3% at 9 mg and 12.5% at 12 mg, against 0.9% on placebo. This is the side effect most specific to retatrutide.
• Injection-site reactions. Redness, welts and itching, which are probably more common with unregulated vials and home reconstitution.
• Higher resting heart rate and palpitations. Most posters describe a modest rise. A few describe palpitations that led to an emergency visit. People taking stimulant ADHD medication asked about combining the two more than once. In the Phase 2 trial, heart-rate increases were dose-dependent, peaked at 24 weeks and declined after that.
• Gastrointestinal effects. Users mention nausea, constipation and diarrhoea less often than with tirzepatide, but the trials show they are the most common side effect overall. At 12 mg in TRIUMPH-1, 42.4% had nausea, 32.0% diarrhoea, 26.1% constipation and 25.3% vomiting.
• Fatigue, low mood or flattened enjoyment. Several users described lower energy, and a few described anhedonia.
• Loose skin and muscle-loss worries. These come with large, fast weight loss and are not specific to retatrutide.

In TRIUMPH-1, 4.1% at 4 mg, 6.9% at 9 mg and 11.3% at 12 mg stopped treatment because of adverse events, compared with 4.9% on placebo. That is the clearest signal of how tolerable the drug is at full dose. For comparison, 6.2% stopped for adverse events on 15 mg tirzepatide in SURMOUNT-1, against 2.6% on placebo.

What questions do users ask most?

Evidence tier: 4 — counts come from our classified Reddit dataset; no approved prescribing information exists to answer them.

More than half of the posts were dosing questions. The recurring ones:

• How to switch from tirzepatide. At least six threads asked about moving from tirzepatide to retatrutide. Several users said appetite suppression felt weaker at first than on tirzepatide.
• What to do at a plateau. Users asked whether to raise the dose after a two- to three-week stall.
• Reconstitution maths. About 25 posts asked about mixing vials with bacteriostatic water, which no approved product requires.
• Stacking. Users asked about adding GHK-Cu, MOTS-c, CJC-1295/ipamorelin or tesamorelin. There is no trial data for any of these combinations.

None of these have answers from approved prescribing information, because none exists yet. Dose, escalation and switching are decisions for a prescriber. Our dosing article covers what the trials used, and switching between GLP-1s covers what is known about moving between approved drugs.

Why are user reports riskier than the trial results?

Evidence tier: 2 — regulatory statements from the FDA's page on unapproved GLP-1 drugs (content current as of 1 October 2026).

Every community report involves unapproved, uncontrolled product. The FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition (FDA, 2026). It has warned:

• telehealth companies for marketing unapproved drugs such as retatrutide, including directly to consumers;
• ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders;
• outsourcing facilities for repackaging retatrutide;
• companies selling retatrutide and other GLP-1 drugs falsely labelled "for research purposes" or "not for human consumption".

The agency also runs a green-list import alert (66-80) meant to stop GLP-1 active ingredients with potential quality problems at the border. It warns that illegally sold products may contain the wrong ingredient, or too little, too much or none of the active one. Lilly has also sued grey-market sellers.

Posters with unexplained new symptoms, like the skin burning in week two, often asked whether a concentration mistake was to blame. That question cannot be answered without a verified product. If you read reviews to decide whether to use research-grade retatrutide, the more useful questions are covered in whether you can legally buy it and how to read a peptide COA.

When will retatrutide be approved?

Evidence tier: 2 — timelines are company-reported; trial status comes from ClinicalTrials.gov and EU status from EMA's published list.

As of July 2026, Lilly was reported to be planning to submit the US application in the first quarter of 2027. FDA review normally takes months after submission, so approval before late 2027 is unlikely.

The submission rests on three completed Phase 3 trials: TRIUMPH-1 (NCT05929066), TRIUMPH-2 in type 2 diabetes (NCT05929079) and TRIUMPH-3 in cardiovascular disease (NCT05882045). A cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes, with about 10,000 participants, is still running.

In the EU, retatrutide did not appear on EMA's list of new medicines under evaluation (data extracted 5 October 2026), and we found no announced EU filing. See retatrutide EU availability for the European picture. Until approval, the only legitimate access anywhere is through clinical trials, and most of the registered Phase 3 studies are completed or no longer recruiting.

Limitations

This analysis covers five months of public Reddit posts and is self-selected, unverified and subject to keyword-matching error. Theme counts are approximate, and many posts describe several compounds at once. The TRIUMPH figures come from company press releases and topline results; full peer-reviewed publications may differ slightly, and registry enrolment counts differ by a few participants from Lilly's announced figures. Cross-trial comparisons with tirzepatide are indicative only. Nothing here is a dosing recommendation.

The bottom line

User reviews of retatrutide line up with the Phase 3 data: very large weight loss, with skin sensitivity and heart-rate effects that show up more than they do on older GLP-1 drugs. The difference is that users take product with no verified identity or dose, without medical supervision. Until approval, the trial results are the reliable picture, and the user reports are a guide to what to ask a clinician.

Related on this site

• Retatrutide peptide profile
• Tirzepatide peptide profile
• Retatrutide deep dive
• Retatrutide vs tirzepatide
• Can you legally buy retatrutide?
• Retatrutide dosing: what the trials used
• Retatrutide EU availability
• GLP-1 side effects and how to manage them

References

• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). NCT05929066
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2). NCT05929079
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). NCT05882045
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5). NCT06662383
• Jastreboff AM, Kaplan LM, Frías JP, et al. 2023. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 389(6):514-526. PMID 37366315 · doi:10.1056/NEJMoa2301972
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 · doi:10.1056/NEJMoa2206038
• US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 1 October 2026; accessed 3 November 2026).
• European Medicines Agency. Applications for new human medicines under evaluation by the CHMP, October 2026 (data extracted 5 October 2026).
• Eli Lilly and Company. 21 May 2026. Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1, NCT05929066). Press release
• Pharmacy Times. 24 July 2026. Lilly prepares for retatrutide FDA filing following additional Phase 3 data in diabetes, CVD (TRIUMPH-2, TRIUMPH-3). Article
• MyPeptideStory Reddit signal dataset, retatrutide subset (n=301, 8 June to 3 November 2026). Anonymised; methodology at peptide community insights.